Publications

Annals of oncology : official journal of the European Society for Medical Oncology

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.

01-08-2018

American journal of clinical dermatology

Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives.

01-06-2018

The New England journal of medicine

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

10-05-2018

Melanoma research

Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.

01-04-2018

ESMO open

Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management.

02-02-2018

Nature medicine

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.

01-02-2018

European journal of cancer (Oxford, England : 1990)

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

01-11-2017

Urology

Observation After Cytoreductive Nephrectomy in Patients With Synchronous Not Completely Resected Metastases of Renal Cell Carcinoma.

01-11-2017

JCO precision oncology

Profound Immunotherapy Response in Mismatch Repair-Deficient Breast Cancer.

01-11-2017

Lancet (London, England)

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

21-10-2017

Nature

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.

12-10-2017

Nature

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.

07-09-2017

European journal of cancer (Oxford, England : 1990)

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF^V600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

01-07-2017

Annals of oncology : official journal of the European Society for Medical Oncology

Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience.

01-04-2017

European journal of cancer (Oxford, England : 1990)

Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients.

01-03-2017

Annals of oncology : official journal of the European Society for Medical Oncology

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.

01-03-2017

Oncoimmunology

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.

27-01-2017

Acta oncologica (Stockholm, Sweden)

Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands.

01-01-2017

Journal of clinical pharmacology

Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.

01-01-2017

Ecancermedicalscience

Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation.

21-12-2016

International journal of molecular sciences

Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in Pten^LoxP/LoxP;Braf^CA/+ Mice.

20-12-2016

The Lancet. Oncology

Biomarkers for outcome upon MAPK inhibition in melanoma.

01-12-2016

Clinical cancer research : an official journal of the American Association for Cancer Research

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.

15-11-2016

Cell metabolism

LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells.

08-11-2016

European journal of cancer (Oxford, England : 1990)

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.

01-11-2016

Journal of clinical pharmacology

The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients.

01-10-2016

Cancer immunology, immunotherapy : CII

Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma.

01-09-2016

European journal of cancer (Oxford, England : 1990)

Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab.

01-09-2016

World journal of urology

Resection of metastasis and local recurrences of renal cell carcinoma after presurgical targeted therapy: probability of complete local control and outcome.

01-08-2016

World journal of urology

Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy.

01-08-2016

Nederlands tijdschrift voor geneeskunde

[No hair loss, but colitis or pneumonitis: unique side effects of immune checkpoint inhibitors for cancer].

22-07-2016

Cell reports

BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts.

28-06-2016

Clinical cancer research : an official journal of the American Association for Cancer Research

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.

15-06-2016

Annals of oncology : official journal of the European Society for Medical Oncology

Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma.

01-06-2016

Cancer immunology, immunotherapy : CII

Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.

01-06-2016

Science (New York, N.Y.)

CANCER IMMUNOLOGY. The "cancer immunogram".

06-05-2016

Clinical cancer research : an official journal of the American Association for Cancer Research

Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells.

01-05-2016

Science (New York, N.Y.)

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

09-10-2015

Cancer immunology, immunotherapy : CII

Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.

01-10-2015

Molecular therapy : the journal of the American Society of Gene Therapy

Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor.

01-09-2015

EMBO molecular medicine

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.

01-09-2015

The Lancet. Oncology

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

01-08-2015

Seminars in oncology

Toxicity patterns with immunomodulating antibodies and their combinations.

01-06-2015

European journal of cancer (Oxford, England : 1990)

Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.

01-03-2015

International immunology

Therapeutic use of anti-CTLA-4 antibodies.

01-01-2015

Nature communications

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

15-12-2014

Science translational medicine

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.

17-09-2014

Cancer immunology, immunotherapy : CII

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.

01-05-2014

Nature

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

03-04-2014

The Lancet. Oncology

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

01-04-2014